By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nevro Corp 

1800 Bridge Parkway

Redwood City  California  94065  U.S.A.
Phone: 650-251-0005 Fax: n/a


Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.

We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).

We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1

The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.

Please click here for job opportunities at Nevro.

Key Statistics

Ownership: Public

Web Site: Nevro
Symbol: NVRO

Medical Device

Company News
Nevro (NVRO) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Outlook 2/24/2017 7:32:55 AM
Nevro (NVRO) To Report Operating Results For The Fourth Quarter And Full Year 2016 2/10/2017 11:26:52 AM
Could Boston Scientific (BSX) Be Nervous About Nevro? 12/14/2016 6:31:08 AM
Nevro Announces Filing Of Lawsuit By Boston Scientific (BSX) 12/12/2016 6:38:24 AM
Nevro Files Lawsuit For Patent Infringement Against Boston Scientific (BSX) In The U.S. 11/29/2016 7:59:30 AM
Nevro Reports Third Quarter 2016 Financial Results 11/8/2016 12:47:11 PM
Nevro To Report Operating Results For The Third Quarter 2016 10/25/2016 9:16:39 AM
Nevro Release: Publication Of Two-Year SENZA-RCT Results In Neurosurgery Demonstrates Sustained Superiority Of HF10 Therapy Over Traditional Spinal Cord Stimulation For Chronic Pain 9/6/2016 8:39:32 AM
Nevro To Present At Upcoming Investor Conferences 8/26/2016 7:46:32 AM
Nevro Reports Second Quarter 2016 Financial Results 8/9/2016 8:23:02 AM